Status:
COMPLETED
US Inhaled Insulin Dose Titration Study
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Sanofi
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study will examine how to dose Exubera (inhaled insulin) in patients who are not well controlled on two or more diabetes pills. This study should show that a large number of patients enrolled in ...
Eligibility Criteria
Inclusion
- Male and female, age \>= 18 years and \<= 80 years, with a diagnosis of type 2 diabetes made at least 6 months prior to study entry, with hemoglobin A1C 7.5-10%
- Currently treated with 2 or more oral antidiabetic agents (sulfonylureas, metformin, and/or thiazolidinediones)
Exclusion
- Type 1 diabetes
- Smoking within the past 6 months or significant pulmonary diseases
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00246623
Start Date
November 1 2005
End Date
March 1 2007
Last Update
February 8 2008
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States
2
Pfizer Investigational Site
Los Angeles, California, United States
3
Pfizer Investigational Site
New Britain, Connecticut, United States
4
Pfizer Investigational Site
Norwalk, Connecticut, United States